Liquidia Corporation LQDA reported a loss for the second quarter on Tuesday.The company posted a second-quarter loss of 49 cents, missing the consensus of a loss of 43 cents. Sales reached $8.84 million compared to the consensus of $3.86 million.In its second-quarter earnings release, the company said that in July and August 2025 it analyzed interim data from the 52-week, prospective, open-label ASCENT study, which fully enrolled 54 patients with pulmonary hypertension associated with interstitial lung dise ...

Product & Approval - YUTREPIA (treprostinil) inhalation powder has received FDA approval [1,3] - YUTREPIA offers a new choice to treat PAH & PH-ILD [11] - The WAC price for a 28-day supply is $24,360, at parity with Tyvaso DPI® [23] Clinical Data & Dosing - YUTREPIA enables a wide range of dosing for both naïve and transition patients [16] - In the INSPIRE study, cough was observed in 27% of transitioning patients and 55% of naïve patients [17] - In the ASCENT study, the median dosing at Week 8 was 132.5 mcg [20] Market & Commercialization - The company is targeting 6,500 physicians treating PH, ILD, or both [27] - The commercial team is fully mobilized and will start detailing today [26] - The field force includes 60 commercial team members, 10 medical science liaisons, field reimbursement specialists, 140 specialty centers and 650 community accounts [27] Patient Support - The company offers full patient support services, including a voucher program, co-pay program, bridge program, and patient assistance program [24]